Investment Advisory Group LLC Trims Stock Position in Johnson & Johnson (NYSE:JNJ)

Investment Advisory Group LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,883 shares of the company’s stock after selling 207 shares during the period. Investment Advisory Group LLC’s holdings in Johnson & Johnson were worth $791,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $27,000. MFA Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $43,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $46,000. Grayhawk Investment Strategies Inc. raised its stake in shares of Johnson & Johnson by 528.6% in the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares during the period. Finally, Fairway Wealth LLC raised its stake in shares of Johnson & Johnson by 217.1% in the 2nd quarter. Fairway Wealth LLC now owns 333 shares of the company’s stock valued at $49,000 after acquiring an additional 228 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on JNJ shares. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. TD Securities dropped their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. The Goldman Sachs Group dropped their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $175.00 to $178.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $174.31.

Johnson & Johnson Stock Up 1.6 %

NYSE JNJ traded up $2.53 on Tuesday, hitting $164.14. 10,546,562 shares of the stock were exchanged, compared to its average volume of 7,050,088. The company has a 50-day moving average price of $162.60 and a 200-day moving average price of $154.48. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market cap of $395.02 billion, a PE ratio of 10.07, a PEG ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter in the prior year, the business posted $2.80 EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. Sell-side analysts anticipate that Johnson & Johnson will post 10 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s payout ratio is 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.